Welcome from the President
BAUS at war
Goliath – RCT evidence that Greenlight 180-W XPS provides benign prostatic hypertrophy (BPH) patients with better return to stable health status within 24 hours, and shorter length of stay, than TURP. United Kingdom results : 1
Long term follow up of a prospective randomised trial of Hexylaminolevulinate (HEXVIX®) photodynamic diagnosis (PDD) assisted versus conventional white-light transurethral resection (TURBT) in newly presenting non-muscle invasive bladder cancer (NMIBC) : 2
Epigenetic Drivers of Penile Squamous Cell Carcinoma Development : 3
Hes6 drives a critical androgen receptor (AR) transcriptional program to induce castration resistant prostate cancer (CRPC) through activation of an E2F1-mediated cell cycle network : 4
INPP4B Knockdown Confers Cisplatin Sensitivity in Bladder Cancer : 5
Factors predicting local recurrence of penile carcinoma (PC) – An analysis of risk factors, patterns of recurrence and outcome : 6
Comparison of radical treatment and mortality in patients with non-metastatic prostate cancer in England and USA : A1
MAPPED: Magnetic resonance imaging in Primary Prostate cancer after Exposure to Dutasteride: Reduction in tumour volume at 6 months in men on active surveillance for prostate cancer : A2
A retrospective cohort comparison study of the LRP and RARP learning curve : A3
A competing-risks analysis of clinical outcomes in a fourteen-year cohort of patients treated with prostate LDR brachytherapy at a single centre : A4
Laparoscopic radical prostatectomy for high-risk prostate cancer : A5
Is outcome following radical prostatectomy determined by race? : A6
The Predictive Value of 2-Year Post-Treatment Biopsy After Prostate Cancer Conformal Radiotherapy For Future Overall Survival and Biochemical Failure. The results of the UK MRC T01 Trial : A7
Focal Salvage HIFU for Radiorecurrent Prostate Cancer: Disease control outcomes : A8
Radical therapy may reduce mortality in men with metastatic prostate cancer : A9
Changing Trends in Radical Prostatectomy (RP) practice across England over 5 years : B1
Comparative cancer mortality outcomes of primary radical therapy for localised prostate cancer in a UK unscreened population : B2
Surgeon-reported perioperative nephrectomy outcomes: Results from 6042 operations recorded on the BAUS nephrectomy database : B3
Matched pair analysis of open and laparoscopic techniques for the management of renal cell carcinoma : B4
The contemporary UK practice of benign nephrectomy: results from the BAUS nephrectomy audit : B5
Partial versus Radical Nephrectomy for T1 renal tumours: an analysis from the British Association of Urological Surgeons Nephrectomy Audit : B6
Indicative operative numbers in urology training – can operative competency be achieved by CCT? : B7
Radical Cystectomy: A National Audit from the UK A review of 5321 radical cystectomy (RC) procedures from the British Association of Urological Surgeons (BAUS) Section of Oncology dataset : P1
Radical Cystectomy Survival in England : P2
Trends in T1/T2 bladder cancer survival in England: A population based study : P3
CYR61 as a novel therapeutic target in muscle invasive bladder cancer : P4
Genome-Wide DNA Methylation Analysis of a High Risk Non-Muscle Invasive Bladder Cancer Cohort Reveals Potential Novel Prognostic Biomarkers : P5
Are We Finally Closer to Predicting the Outcome to Intravesical BCG Immunotherapy for Bladder Cancer? The T-cell Response Offers Promising Results : P6
Pre-operative electromotive drug administration of mitomycin C (EMDA-MMC) in newly diagnosed non muscle invasive bladder cancer (NMIBC): A pilot feasibility study : P7
The safety and efficacy of intravesical Mitomycin-C hyperthermia in the management of high-risk non-muscle invasive bladder cancer: A seven-year experience : P8
Outpatient Holmium: YAG laser ablation of non-muscle invasive bladder cancer is safe and efficacious; results of a large retrospective UK case series : P9
Sequential BCG/electromotive drug administration (EMDA) mitomycin C (MMC) as the standard intravesical regimen in high risk non muscle invasive bladder cancer (NMIBC) – one year outcomes : P10
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer : P11
Metastases at presentation of transitional cell muscle invasive bladder carcinoma in a 10 year series of 427 patients: is staging computed tomography of the thorax always required? : P12
P21-activated kinase 5 (PAK5) and epithelial mesenchymal transition in bladder cancer : P13
Genomic Mutations in Bladder Cancer : P14
Prostate Cancer Mediated Differentiation of Bone-Marrow Derived Mesenchymal Stem Cells Facilitates Prostate Cancer Cell Invasive and Migratory Capacity : P15
Similar Expression to FGF (Sef) alters Epithelial to Mesenchymal Transition related genes in prostate cancer : P16
Elevated HERV-K Expression in PBMC is Associated with a Diagnosis of Prostate Cancer among Older Men and Current Smokers : P17
Multi-transcript profiling in diagnostic archival needle biopsies to identify predictive biomarkers of non-surgical therapy outcome in prostate cancer : P18
The Mutational Landscape of Penile Squamous Cell Carcinoma : P19
p16 INK4A expression shows poor correlation with presence of HPV DNA in penile carcinoma : P20
Development of a tubularised urethral substitute using a novel nanocomposite polymer : P21
Impact of interleukin-18 gene + 105 A > C polymorphism with kidney stone disease. A study in Kasmiri population : P22
Evaluating the quality of operative notes following transurethral resection of bladder lesions : P23
Variability in the quality of decision-making processes in urology multidisciplinary teams compared to other cancer specialties : P24
Consultant delivered one stop clinics are efficient, and do not lead to missed diagnoses : P25
Risk factors for 30-day surgical adverse events and hospital readmission among major urological cancers resection surgery : P26
Factors influencing length of stay and suitability for early community discharge in the management of Acute Pyelonephritis (APN) : P27
Challenging the guidelines: Is current cumulative radiation exposure in patients treated with partial nephrectomy safe? : P28
Radiation Exposure in Urological Procedures: Are Patients and Staff at Unnecessary Risk? : P29
Is routine ‘group and hold (G&S)’ blood sampling a necessary in patients undergoing Trans-Urethral Resection of the Prostate (TURP) Surgery? Is it a cost effective addition to patient safety? : P30
Urethral catheter care documentation: Are we doing it right? : P31
Stable prostate cancer discharge – a locally enhanced service : P32
Does a urology study day improve medical students’ core knowledge and skills? : P33
Effectiveness of learning Holmium Laser Enucleation of the Prostate in a virtual reality simulation environment – a validation study : P34
Prevalence of ciprofloxacin resistant E. coli in rectal swabs prior to TRUS biopsy of prostate : P35
Using Clinical Audit to Improve Sepsis Rates Post-TRUS Biopsy : P36
Partial Nephrectomy in England in 2012 : P37
Who dies from nephrectomy and why do they die? : P38
Photodynamic Diagnostic Ureterorenoscopy: An essential tool for upper urinary tract tumour diagnosis and treatment : P39
Ex-vivo partial nephrectomy and renal auto-transplantation for complex renal malignancies : P40
Cystoscopic surveillance following nephroureterectomy – can we stratify according to upper tract tumour characteristics? : P41
Contemporary management of renal tumours with caval involvement: results from the 2012 BAUS nephrectomy audit : P42
Surgical outcomes for cytoreductive nephrectomy in tyrosine kinase inhibitor treated and untreated patients: a matched pair analysis : P43
A single centre comparison of robotic and open partial nephrectomy with radio-frequency ablation for the treatment of small renal masses : P44
The learning curve for robotic-assisted partial nephrectomy, 100 case statistical analysis : P45
A critical review of the risks and benefits of planned simultaneous urological and cardiac surgery for complex tumours involving the IVC : P46
Intermediate term oncologic outcomes of renal cryoablation: A single centre analysis : P47
Surgical Approach in performing robotic assisted partial nephrectomy – the first 100 cases in a UK Unit : P48
Percutaneous radiofrequency ablation of small renal masses: The Wales experience : P49
PSA Surveillance in Renal Transplant Recipients : P50
Urinary engrailed-2 levels in healthy volunteers, patients on active surveillance and following radical prostate cancer treatment : P51
The use of transperineal sector biopsy as a first-line biopsy strategy: A multi-institutional analysis of clinical outcomes and complications : P52
The Role of Transperineal Template Prostate Biopsies in Prostate Cancer Diagnosis in biopsy naïve men with PSA less than 20 ng/mL : P53
Transperineal prostate (TP) biopsies – The first prospective evaluation of patient reported experience and effects on symptoms and life style : P54
Transperineal biopsy related erectile dysfunction in Active Surveillance : P55
Multiparametric Magnetic Resonance Imaging (mpMRI) of Prostate Cancer lesions – How much do we have to learn? : P56
MRI Invisible prostate cancer: The role of systematic biopsy outside the MRI lesion : P57
How well does mp-MRI PiRADS scoring predict the outcome of transperineal sector prostate biopsy? : P58
Diagnostic MRI prostate pre-biopsy is associated with a significant false negative rate : P59
Re-examining the role of whole body Bone Scan in staging prostate cancer : P60
Interim Analysis of the Long-term Efficacy and Safety of Repeat OnabotulinumtoxinA in the Treatment of Overactive Bladder and Urinary Incontinence, Median 2.4 Years’ Follow up : P61
Decreasing the dose of onabotulinum toxin A from 300 units to 200 units in multiple sclerosis patients – Does it matter? : P62
Cost comparison of sacral nerve stimulation and OnabotulinumtoxinA to manage urinary incontinence in patients with overactive bladder : P63
Can mirabegron reduce the waiting list for repeat intravesical Botulinum injections? : P64
Validating a New Nomogram for Diagnosing Bladder Outlet Obstruction in Women : P65
Open label pilot study of urethral injections of Botulinum toxin to treat women in urinary retention due to a primary disorder of urethral sphincter relaxation (Fowler's syndrome) : P66
Long term follow-up of a multicentre randomised controlled trial comparing TVT, Pelvicol (TM) and autologous fascial slings for the treatment of stress urinary incontinence in women : P67
Systematic review and meta-analysis of the artificial urinary sphincter in men undergoing prior external beam radiotherapy : P68
Vesico-vaginal fistula repair: Does route of repair affect patient outcome? : P69
The long-term outcome of bipolar plasma enucleation in large BPH cases – The test of time in a prospective, randomized comparison to open prostatectomy : P70
Prostate artery embolization (PAE) for bladder outflow obstruction: Results of the first UK prospective study : P71
Dynamic Sentinel Lymph Node Biopsy in Penile Cancer: A Single Centre Experience : P72
Does combined Dynamic Sentinel Lymph Node Biopsy and SPECT/CT improve sentinel node detection rates in penile cancer? : P73
Contemporary retroperitoneal lymph node dissection (RPLND) for testis cancer in the UK – a national study : P74
One stage hypospadias reconstruction in adults : P75
Which stricture-related factors influence the outcome of urethroplasty? : P76
Failure of first stage penile urethroplasty using buccal mucosal graft – causes and outcome of revision surgery : P77
Long-term patient reported outcome of bothersome oral symptoms following Buccal Mucosal Graft (BUMG) harvest for urethral reconstruction : P78
Outcome of redo-bulbar and membranous urethroplasty : P79
Six year follow up of the patients undergoing the Nesbit procedure for penile curvature : P80
Plaque surgery with insertion of malleable penile prosthesis for severe Peyronies Disease -a real length improvement : P81
Replacement and revision Artificial Urinary Sphincter (AUS) surgery compared to primary implantation : P82
Urological Trauma in a Level 1 trauma centre: Follow up data : P83
The long-term (20–30 year) outcome of cystoplasty : P84
Is there a relationship between standard semen parameters (SSP), age and DNA fragmentation in men undergoing assisted reproductive techniques (ART)? : P85
Does Hospital Volume Affect Outcome after Percutaneous Nephrolithotomy in England? Results from the Hospital Episode Statistics Database : P86
Evaluation of Hounsfield Units in Cystinuria patients : P87
What makes percutaneous nephrolithotomy more morbid? A UK Endourology perspective : P88
Experience with Ultra-mini PCNL : P89
Efficacy of dietary and thiazide treatment of hypercalciuria in recurrent stone formers : P90
Mini-Percutaneous Nephrolithotomy in the Treatment of Renal Nephrolithiasis in Adults: A Single Institution Experience : P91
Dual Energy CT scanning in the management of urolithiasis : P92
Tamsulosin is effective at facilitating expulsion of both renal and ureteric stone following extracorporeal shock wave lithotripsy: a meta-analysis : P93
A Pilot Study of a Patient Reported Outcome Measure (PROM) for Percutaneous Nephro-lithotomy (PCNL) : P94
Developing a disease specific Ureteric Stone Patient reported outcome measure: Stage 1&2 : P95
Modified technique of Tubeless PCNL using antegrade tether: a randomized study : P96
Multicentre UK experience of sex cord stromal tumours : P97
Testis – Sparing Surgery for Small Testicular Lesions – Can Multi-Parametric Ultrasound (MP-US) aid Patient Selection? : P98
Is Histological Analysis Necessary Following Laser Transurethral Vaporesection of the Prostate? : P99
Is estimated GFR sufficient for the measurement of renal function after cystectomy and ileal loop diversion? : P100
The Impact of Music on Pain and Anxiety Experienced in Patients Undergoing Flexible Cystoscopy: A Prospective Randomized Controlled Trial : P101
Post-operative UTI: How are they different from pre-operative UTI? : P102
The use of intravesical gentamicin to treat recurrent urinary tract infections : P103
Lower urinary tract assessment and treatment in patients undergoing subcutaneous implantation of a battery powered catheter drainage system for managing refractory ascites : P104
Outcomes following paediatric one stage inguinal orchidopexy for palpable cryptorchidism within two none-paediatric specialist centres : P105
The role of an adult urologist with a paediatric urology interest in a District General Hospital : P106
Understanding and solving the challenges of Retroperitoneal Fibrosis (RPF) – lessons learnt from a multidisciplinary service : P107
Impact of the ‘Blood in Pee’ Pilot Campaign : P108
The commercialisation of Urine in Ancient Rome : U1
Urethral sounds: Otis to Clutton : U2
The introduction of the Cystoscope into the British Isles : U3
The humble struvite stone: From its discovery to the modern day : U4
The Disability of King James I : U5
The Management of Urological Conditions in Anglo Saxon England : U6
Hugh Hampton Young: One of a Kind : U7
An History of Penile Prostheses : U8
‘One sex, two genders’: Evolution of the two-sex theory : U9
Flowing Through the Ages: A History of Uroflowmetry : U10
History of Bladder Pain Syndrome (Interstitial Cystitis) : U11
The discovery and history of Balkan Endemic Nephropathy : U12
From Lister to Laparoscopy: 100 years of urology in South East London : U13
A History of the Management of Male Urinary Incontinence : U14
The role of the Royal Society of Medicine and BAUS in the development of British Urology : U15